Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Olumiant ® (baricitinib)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Olumiant® (baricitinib): Incidence of Alopecia in Atopic Dermatitis
There was no significant difference between the baricitinib and placebo group or between baricitinib doses in the incidence of alopecia.
UK_cFAQ_BAR150B_ALOPECIA_TEAE_AD
en-GB
Incidence of Alopecia in the BREEZE-AD Clinical Development Program
Dataset Description
The integrated datasets used to evaluate incidence of alopecia are described in more detail in Integrated Analysis Datasets Used to Evaluate Safety in Atopic Dermatitis Clinical Trials.
Incidence of Treatment-Emergent Alopecia Adverse Events
Alopecia, diffuse alopecia, alopecia areata, and androgenetic alopecia were reported as TEAEs in patients who received BARI.
There were no statistically significant differences (p<.05) in the incidence of alopecia between the BARI and placebo group or between BARI doses.1
|
|
|
|
|
|
|
|
|
|
|
BARI 2 mg vs 4 mg ext |
All BARI AD |
|||||||
Placebo |
BARI 2 mg |
Placebo |
BARI 4 mg |
BARI 2 mg |
BARI 4 mg |
BARI 2 mg |
BARI 4 mg |
All doses |
|
Alopecia |
6 (0.7) |
3 (0.5) |
5 (0.6) |
2 (0.4) |
3 (0.5) |
2 (0.4) |
4 (0.7) [1.0] |
3 (0.6) [0.7] |
11 (0.4) [0.5] |
Diffuse Alopecia |
0 |
3 (0.3) |
0 |
0 |
2 (0.2) |
0 |
2 (0.2) [0.3] |
0 (0) [0] |
6 (0.2) [0.3] |
Alopecia Areata |
1 (0.1) |
1 (0.2) |
1 (0.1) |
2 (0.4) |
1 (0.2) |
2 (0.4) |
1 (0.2) [0.3] |
2 (0.4) [0.4] |
5 (0.2) [0.2] |
Androgenetic Alopecia |
0 |
1 (0.1) |
0 |
0 |
1 (0.1) |
0 |
1 (0.1) [0.2] |
0 (0) [0] |
1 (0.0) [0.0] |
Abbreviations: AD = atopic dermatitis; adj = adjusted; BARI = baricitinib; ext = extended; IR = incidence rate.
aData through 16-week placebo-controlled period.
bFor the integrated controlled analysis sets where the randomized ratio of patients receiving BARI to placebo or BARI to active control is not the same across all the integrated studies (example 2:1:1:1 vs 1:1:1:1), the study-size adjusted percentages were calculated for the adverse events to provide appropriate direct comparisons between treatment groups.
Integrated Safety Datasets Description
Analysis Set |
Description |
BARI 2 mg Placebo-Controlled Studies: JAHG, BREEZE-AD1, BREEZE-AD2, BREEZE- AD4, BREEZE- AD5, and BREEZE-AD7 |
Compares BARI 2 mg vs placebo Includes patients with AD from 1 phase 2 and 5 phase 3 studies who were randomized to
Treatment period was 0 to 16 weeks. |
BARI 4 mg Placebo-Controlled Studies: JAHG, BREEZE-AD1, BREEZE-AD2, BREEZE- AD4, and BREEZE-AD7 |
Compares BARI 4 mg vs placebo Includes patients with AD from 1 phase 2 and 4 phase 3 studies who were randomized to
Treatment period was 0 to 16 weeks. |
BARI 2 mg vs 4 mg Studies: JAHG, BREEZE-AD1, BREEZE-AD2, BREEZE-AD4, and BREEZE-AD7 |
Compares BARI 2 mg vs BARI 4 mg through 16 weeks Includes patients with AD from 1 phase 2 and 4 phase 3 studies who were randomized to
Treated for 0 to 16 weeks during the placebo-controlled period. |
BARI 2 mg vs 4 mg Extended Studies: JAHG, BREEZE-AD1, BREEZE-AD2, BREEZE-AD4, BREEZE-AD7, and extension study BREEZE-AD3 |
Compares BARI 2 mg vs BARI 4 mg including extended evaluations Includes patients with AD from 1 phase 2 and 4 phase 3 studies and any further exposure for those patients in the phase 3 extension study, BREEZE-AD3, who were randomized to
Data censored at dose or treatment change (rescue, dose switch, or re-randomization to a different BARI dose or placebo) for BREEZE-AD4 and BREEZE-AD3. |
All BARI AD Studies: JAHG, BREEZE-AD1, BREEZE-AD2, BREEZE-AD4, BREEZE-AD5, BREEZE-AD7, and extension studies BREEZE-AD3, BREEZE-AD6 |
No between-group comparisons Includes 2531 (total PYE=2247.4) patients with AD from 1 phase 2, 5 phase 3, and 2 phase 3 extension studies who received BARI at a variety of doses, including
Includes all patients who were exposed to any BARI dose at any time during the studies, either from randomization or from switch or rescue from placebo. No censoring of data at dose change. |
Abbreviations: AD = atopic dermatitis; BARI = baricitinib; PYE = patient-years of exposure.
Note: BARI 1 mg was studied in pivotal trials, however it is not approved. Please refer to section 4.2 of the Olumiant Summary of Product Characteristics for approved dosage.
References
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
3Bieber T, Thyssen JP, Reich K, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2021;35(2):476-485. https://doi.org/10.1111/jdv.16948
Glossary
AD = atopic dermatitis
BARI = baricitinib
TEAE = treatment-emergent adverse event
Date of Last Review: 04 February 2021
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays